Blume-Jensen Peter 4

What Happened

• Peter Blume-Jensen, President, CEO and a director of Acrivon Therapeutics (ACRV), had 1,881 shares withheld to satisfy tax withholding upon the vesting of restricted stock units (RSUs). The filing reports two dispositions on Feb 14, 2026: 1,302 shares withheld at $1.63 each ($2,122) and 579 shares withheld at $1.63 each ($944), totaling $3,066. The transactions are reported with code F (payment of exercise price or tax liability via share withholding) and represent a routine tax-withholding disposition rather than an open-market sale.

Key Details

• Transaction date: 2026-02-14; Filing date: 2026-02-18.
• Prices: $1.63 per share for both disposals.
• Shares withheld/disposed: 1,302 and 579 (total 1,881); total reported value $3,066.
• Transaction code: F — shares withheld to satisfy tax withholding on RSU vesting (footnote F1).
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Related footnotes: F2/F3 note that certain securities are held by Dr. Blume-Jensen and his spouse Dr. Kristina Masson, each disclaiming beneficial ownership of the other's holdings except for pecuniary interest.
• Timeliness: filing date provided; no late-filing flag shown in the supplied data.

Context

• Withholding shares to cover taxes on vested RSUs is a common, routine corporate action and differs from an open-market sale—shares are retained by the issuer to satisfy tax obligations. This type of disposition typically reflects tax mechanics rather than a directional wager on the stock.